Humasis Co. Ltd
Humasis Co. Ltd. manufactures and sells pharmaceuticals and medical devices in South Korea and internationally. It offers immunodiagnostic kits, such as quantitative and qualitative tests, cardiac and cancer markers, infectious diseases, hormones, and women's health. The company also provides bio-material products, such as COVID-19 nucleocapsid protein, human immunodeficiency virus surface protei… Read more
Humasis Co. Ltd (205470) - Total Liabilities
Latest total liabilities as of September 2025: ₩90.75 Billion KRW
Based on the latest financial reports, Humasis Co. Ltd (205470) has total liabilities worth ₩90.75 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Humasis Co. Ltd - Total Liabilities Trend (2014–2024)
This chart illustrates how Humasis Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Humasis Co. Ltd Competitors by Total Liabilities
The table below lists competitors of Humasis Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
China Fineblanking Technology Co Ltd
TWO:1586
|
Taiwan | NT$1.87 Billion |
|
AstroNova Inc
NASDAQ:ALOT
|
USA | $63.95 Million |
|
CrystalGenomics Inc
KQ:083790
|
Korea | ₩124.24 Billion |
|
JTC Inc
KQ:950170
|
Korea | ₩168.85 Billion |
|
NEBAG NA SF 0,02
F:NWR
|
Germany | €42.11K |
|
Precise Corporation Public Company Limited
BK:PCC
|
Thailand | ฿1.72 Billion |
|
Titanium Transportation Group Inc.
TO:TTNM
|
Canada | CA$206.18 Million |
|
Inhibikase Therapeutics Inc
NASDAQ:IKT
|
USA | $6.70 Million |
Liability Composition Analysis (2014–2024)
This chart breaks down Humasis Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.49 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.41 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Humasis Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Humasis Co. Ltd (2014–2024)
The table below shows the annual total liabilities of Humasis Co. Ltd from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩102.65 Billion | +71.14% |
| 2023-12-31 | ₩59.98 Billion | -50.35% |
| 2022-12-31 | ₩120.80 Billion | -12.91% |
| 2021-12-31 | ₩138.71 Billion | +611.03% |
| 2020-12-31 | ₩19.51 Billion | -8.17% |
| 2019-12-31 | ₩21.24 Billion | +16.93% |
| 2018-12-31 | ₩18.17 Billion | +42.74% |
| 2017-12-31 | ₩12.73 Billion | +906.96% |
| 2016-12-31 | ₩1.26 Billion | -70.13% |
| 2015-12-31 | ₩4.23 Billion | +1.78% |
| 2014-12-31 | ₩4.16 Billion | -- |